Cubist Pharmaceuticals, Inc. (NASDAQ:CBST)

motleycrew24 (< 20) Submitted: 1/15/2008 12:02:39 PM : Start Price: $20.66 CBST Score: +93.62

The earnings growth of Cubist of 25-50% per year is expected to continue for several years due to Cubicin alone. What if their Chromium Picolate product catches on in view of the diabetes research that shows promise.

I am surprised that a 50% revenue jump year over year did not kickstart the share value. When this happens again, I think we're in for a nice ride.

TheLudicFallacy (80.11) Submitted: 12/28/2007 2:19:31 AM : Start Price: $21.24 CBST Score: +95.03

Rapid growth in a down market. A company which provides inovation in the critical care enviorment. A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. With a current ratio of 9.7 they are finantially strong, a PE of 28 with revenue growth of 60% and a 5 year growth rate of 112%. Price to FCF of 15 with EPS that went from -0.40 per share last quarter in 2005 to +0.40 last quarter.

NuclearSteve (< 20) Submitted: 8/23/2007 2:42:21 PM : Start Price: $23.45 CBST Score: +74.83

Great earnings. This is currently trading at a 45 multiple and looks like it will grow by 120% in the coming year. It's a bargain.

rocky2door (< 20) Submitted: 8/22/2007 11:05:54 PM : Start Price: $24.04 CBST Score: +71.48

Has the right medicine!

garrgh (49.58) Submitted: 6/3/2007 4:12:34 PM : Start Price: $22.89 CBST Score: +83.22

their new drug is hitting the market, should give a good revenue stream

Daveskii (60.58) Submitted: 4/24/2007 3:44:06 PM : Start Price: $22.06 CBST Score: +86.39

Large market opportunity, undervalued vs. its peer group. Potential takeover candidate.

ambae (< 20) Submitted: 4/2/2007 5:07:16 PM : Start Price: $22.85 CBST Score: +76.81

top r&d team

QuasiProfessor (< 20) Submitted: 2/8/2007 1:51:16 AM : Start Price: $19.19 CBST Score: +110.92

Solid gains in sales. Has a drug that fills the niche for the ever increasing drug resistant Staph infections.

vegskg (< 20) Submitted: 1/30/2007 8:58:13 AM : Start Price: $18.01 CBST Score: -122.88

The company has developed a number of fine products durning my involement with their stock, but has never shown any growth.

VanGundy1 (35.49) Submitted: 1/19/2007 3:16:47 PM : Start Price: $17.70 CBST Score: +127.13

With MRSA on the rise and some good luck this company might just save your life. (And make you money.)

msbdove (31.03) Submitted: 12/17/2006 4:16:34 PM : Start Price: $18.27 CBST Score: +119.86

CBST's recent distribution deal with AstraZeneca bodes well for the company's SuperAntibiotic, Cubisin. if analysts covering the stock have nailed their price targets, investors in CBST could be looking at a nice 60% gain within the next year.

capagator (< 20) Submitted: 12/11/2006 11:19:19 AM : Start Price: $18.40 CBST Score: +117.83

Great need for "super staph" antibiotics exists and this company has a good candidate to fill much of the need.

jhumkey (62.88) Submitted: 10/29/2006 4:15:25 PM : Start Price: $22.52 CBST Score: +75.15

Purely because its cyclical. On about a 6 week cycle. Maxing at 24.79.

PrincetonAl (90.73) Submitted: 10/22/2006 12:20:36 AM : Start Price: $22.29 CBST Score: +76.20

Fundamental bet on a non-dilutive management that will either only in-license complementary anti-infectives, or seek an exit at a premium while reducing expenses. Discounted on short-term weakness and telavancin introduction, if cubicin can continue to expand its approvals, its a 30% discount to fair value. If sales peak next year, its still at fair value (or less) if management slashes expenses, given this a pretty good floor on the downside.

Patrickrom (92.76) Submitted: 10/17/2006 5:58:55 PM : Start Price: $21.84 CBST Score: +80.30

With the success of its anti-infection drugs it should continue to rise and outperform the market.